Wednesday 23rd August 2017

Kenya is among nine countries across Africa and Asia where clinical trials will be conducted for a new anti-malarial drug.

Developed by the Swiss pharmaceutical company Novartis, alongside Medicines for Malaria Venture (MMV), the new medicine – known as KAF156 – is aimed at dealing with the tough-to-treat drug-resistant malaria.

Clinical trials have already begun at one centre in Mali. This will be followed by trials at 16 additional centres, some in Kenya, over the next couple of months.

Read more from The Daily Nation here.